Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics

Set Alert for Generics

Demand Spike Sees Sandoz, Teva Fall Short On US Amoxicillin Supply

Infants and young children across the US are continuing to struggle to get access to one of the most common and recognized antibiotics, liquid-dose amoxicillin, amid a surge in demand for the drug that has hindered generics manufacturers.

Supply Chain Generic Drugs

What’s Next? Five Things To Look Out For In December

In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.

Biosimilars Generic Drugs

Lupin Turns Up Heat With Bausch Brands Acquisition, Perforomist Generic Launch

Two acquisitions of brands in as many months, Lupin has stepped up its game in the Americas. A buyout of nine established Bausch Health brands follows rights to two from Sunovion. While it awaits news on generic(g) Spiriva, the launch of gPerforomist will help expand Lupin’s respiratory franchise

Deals Generic Drugs

IHP’s ‘Big Give’ Will Double The Value Of Donations

UK-based charity International Health Partners is once again doubling the value of donations to its ‘Big Give’ appeal in early December, with this year’s total set to be donated to countries in the Horn of Africa where access to medicines is in jeopardy.

Market Access Generic Drugs

Advanz Zeroes In On Innovative Assets And M&A

Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.

Value-Added Medicines M & A

Accord Unveils New Ventures After A Year Of Change

A year after taking up the lead for Accord in the EMENA region, Paul Tredwell talks to Generics Bulletin in detail about the changes that he has already overseen in the role, as well as unveiling a number of new business initiatives, acquisitions and appointments that form part of his long-term growth strategy.

Strategy Leadership

Sun Pharma Reinforces Position As Indian Industry Leader

Sun Pharmaceuticals continues to dominate the Indian pharmaceutical space while its R&D costs are set to rise.

Sales & Earnings Research & Development

Delisting Of Jazz’s Xyrem Patent In Orange Book Could Spur More Infringement Counterclaims

Jazz’s REMS patent on distribution of Xyrem does not belong in the Orange Book because it is directed to systems rather than a method of using the drug, court rules, agreeing with FTC’s analysis.

Intellectual Property Generic Drugs

India Business Makes Gains At Glenmark While Rest Of World Sees Mixed Results

Glenmark’s domestic business was seen to gradually strengthen its market share during Q2, while its North American division saw a minor decline in growth and a drop in COVID-related sales took its toll.

Sales & Earnings Generic Drugs
See All
UsernamePublicRestriction

Register